Literature DB >> 3513947

Phase II trial of carboplatin in non-small cell lung cancer.

I N Olver, R C Donehower, D A Van Echo, D S Ettinger, J Aisner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3513947

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

1.  Carboplatin and etoposide in advanced lung cancer:--a phase I study.

Authors:  K Liippo; V Nikkanen; E Heinonen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma.

Authors:  P A Reece; J F Bishop; I N Olver; I Stafford; B L Hillcoat; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).

Authors:  P Weynants; Y Humblet; A Bosly; D Schallier; P Duprez; F Majois; M Beauduin; J Prignot; M Symann
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

4.  Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.

Authors:  U Gatzemeier; M Heckmayr; D K Hossfeld; R Zschaber; W Achterrath; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Phase II study of carboplatin in patients with nonresected lung cancer. Japan Cooperative Oncology Group on Lung Cancer.

Authors: 
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination.

Authors:  Emilio Esteban-Gonzalez; Yolanda Fernández; Noemí Villanueva; Joaquin Fra; Isabel Muñiz; Isabel Palacio; Jose M Vieitez; Esther Uña; Beatriz Mareque; Angel J Lacave
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

7.  Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Authors:  Y Sasaki; T Shinkai; K Eguchi; T Tamura; Y Ohe; T Ohmori; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 8.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.